Diamond Hill Capital’s Top Stock Picks

Ric Dillon is head honcho at the $8+ billion Diamond Hill Capital Management. The firm is publicly traded on the NASDAQ under the ticker DHIL and is part of the Russell 2000 Index. Diamond Hill takes long-term approach to capital management and believes heavily in the concept of reversion to intrinsic value. In this article we will take a closer look at Diamond Hill Capital’s top stock picks:

CompanyName Ticker Value Activity
OCCIDENTAL PETROLEUM CORP OXY 279521 -2%
ANADARKO PETROLEUM CORP APC 258996 -1%
UNITED TECHNOLOGIES CORP UTX 246877 -2%
ABBOTT LABORATORIES ABT 226778 -2%
PFIZER INC PFE 213616 -1%
MEDTRONIC INC MDT 210037 -2%
PROCTER & GAMBLE CO PG 205784 1%
MICROSOFT CORP MSFT 192065 -7%
PEPSICO INC PEP 191440 -4%
P N C FINANCIAL SERVICES GRP PNC 181597 -3%

Occidental Petroleum Corporation (NYSE:OXY)

Occidental Petroleum (NYSE: OXY) has been lagging in recent history. We too have not been thrilled by capital spending overruns and awful reserve replacements in the past year and a half. To stem the bloodshed, the company has made a couple moves. It hired a new EVP of Operations, Willie Chiang. He was rumored to be in the running for the top job at Phillips 66 but that went to Greg Garland. Chiang’s expertise has been in refining, so we’re not sure how that will translate into better performance at OXY but we’ll just have to see. With shares below $80, we thought the company would be buying back shares like mad. However, this has not materialized. In Q1 calls, CEO Chazen did indicate that buybacks would take place, and we think they will. If share repurchases get OXY to a 7% cash yield this year, there is no way the stock should trade below $80, especially with improvements in California. We’re in as are Ralph Whitworth, Leighton Welch, and Robert Bishop.

Anadarko Petroleum (NYSE: APC) has been operating smoothly thus far with decent FCF generation. The stock is trading relatively in line with its large cap peers. And though we think there are additional unlocked sources of value in West Africa (offshore), the Gulf of Mexico, and other resource play programs, until the Tronox trial is over, we would not recommend establishing a position. In this $25 billion environmental lawsuit, Tronox and the US government are up against APC and Kerr-McGee that will assign blame for Tronox’s “toxic past.” Chemical maker, Tronox, had filed for Chapter 11 in 2009. In terms of what investors expect, according to a Credit Suisse survey, 65% of respondents believe the valuation embeds more than $1.5 billion for Tronox, including 31% between $1.5 and $2.5 billion and 34% above $2.5 billion. APC management does not seem to want to settle, so we expect this to get dirty.

United Technologies (NYSE: UTX) is an industrial conglomerate with brands like Otis (world’s largest elevator company), Carrier (commercial/residential heating and air-conditioning systems and commercial transport refrigeration equipment), Pratt & Whitney (supplies military and civil aircraft engines and service operations), and Sikorsky (helicopters). UTX is a major player in aerospace and defense as well as global infrastructure, and we think the company can continue to post solid results accompanied by share repurchases given its substantial FCF conversion. However, we don’t see many upcoming catalysts and would prefer a global operator with more ex-US sales (UTX derives 60 percent of sales from the US).

Abbott Laboratories (NASDAQ: ABT), like other big pharma companies, faces a looming patent cliff. It currents dominates the autoimmune market, an estimated $25 billion market that includes treatment for rheumatoid arthritis, Crohn’s disease, Addison’s disease, multiple sclerosis, and type I diabetes. ABT’s Humira is the world’s best-selling drug in the autoimmune market, with an estimated market share of well over 30% (mostly to treat rheumatoid arthritis). 2011 Humira revenues were over $8 billion, and we think this could accelerate to $10.5 billion by 2013. However, ABT’s HIV antiviral, Kaletra, has been losing market share in part because of exclusion from the list of preferred treatment options in some US Department of Health and Human Services’ (DHHS) guidelines. Overall ABT has a decent pipeline but we prefer pharma companies with catalysts and a strong pipeline like Pfizer (read more on Why Hedge Funds Love Pfizer).

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!